Market Closed -
Nasdaq
04:00:00 2024-05-24 pm EDT
|
5-day change
|
1st Jan Change
|
2.13
USD
|
+0.47%
|
|
-11.62%
|
-29.24%
|
Fiscal Period: December |
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
541.3
|
274.4
|
166
|
117.5
|
-
|
-
|
Enterprise Value (EV)
1 |
335.8
|
169.6
|
166
|
-9.496
|
86.55
|
3.954
|
P/E ratio
|
-3.71
x
|
-2.67
x
|
-1.67
x
|
-1.69
x
|
-1.76
x
|
-1.67
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
3,759
x
|
132
x
|
53.6
x
|
26.4
x
|
92.4
x
|
4.34
x
|
EV / Revenue
|
2,332
x
|
81.8
x
|
53.6
x
|
-2.13
x
|
68.1
x
|
0.15
x
|
EV / EBITDA
|
-5.2
x
|
-1.68
x
|
-
|
0.1
x
|
-0.67
x
|
-0.03
x
|
EV / FCF
|
-5.68
x
|
-1.7
x
|
-
|
0.1
x
|
-1.06
x
|
-0.03
x
|
FCF Yield
|
-17.6%
|
-58.9%
|
-
|
969%
|
-94.7%
|
-2,883%
|
Price to Book
|
-
|
-
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
47,775
|
48,049
|
55,142
|
55,155
|
-
|
-
|
Reference price
2 |
11.33
|
5.710
|
3.010
|
2.130
|
2.130
|
2.130
|
Announcement Date
|
3/10/22
|
3/1/23
|
3/28/24
|
-
|
-
|
-
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
-
|
0.144
|
2.073
|
3.094
|
4.448
|
1.271
|
27.05
|
EBITDA
1 |
-
|
-64.64
|
-101.2
|
-
|
-91.72
|
-129.8
|
-150.2
|
EBIT
1 |
-
|
-66.03
|
-102.8
|
-100.3
|
-85.06
|
-102.9
|
-154.2
|
Operating Margin
|
-
|
-45,855.56%
|
-4,957.36%
|
-3,240.5%
|
-1,912.29%
|
-8,090.22%
|
-570.18%
|
Earnings before Tax (EBT)
1 |
-
|
-68.28
|
-102.7
|
-97.43
|
-77.82
|
-92.87
|
-138.9
|
Net income
1 |
-29.45
|
-68.28
|
-102.7
|
-97.43
|
-77.82
|
-92.87
|
-138.9
|
Net margin
|
-
|
-47,416.67%
|
-4,954.22%
|
-3,148.93%
|
-1,749.49%
|
-7,304.45%
|
-513.45%
|
EPS
2 |
-7.556
|
-3.050
|
-2.140
|
-1.800
|
-1.264
|
-1.212
|
-1.275
|
Free Cash Flow
1 |
-
|
-59.08
|
-99.9
|
-
|
-92
|
-82
|
-114
|
FCF margin
|
-
|
-41,025%
|
-4,818.86%
|
-
|
-2,068.19%
|
-6,449.43%
|
-421.49%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
7/9/21
|
3/10/22
|
3/1/23
|
3/28/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
2025 Q2
|
---|
Net sales
1 |
0.144
|
0.268
|
0.476
|
0.595
|
0.735
|
0.516
|
0.759
|
0.831
|
0.989
|
2.36
|
0.6071
|
0.6071
|
0.6071
|
0.5875
|
0.5375
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-20.66
|
-19.96
|
-25.85
|
-25.98
|
-30.97
|
-25.82
|
-30.84
|
-22.9
|
-20.7
|
-20.45
|
-21.27
|
-21.25
|
-21.89
|
-17.33
|
-18.19
|
Operating Margin
|
-14,350%
|
-7,447.39%
|
-5,431.51%
|
-4,367.23%
|
-4,213.2%
|
-5,003.49%
|
-4,063.24%
|
-2,756.08%
|
-2,092.92%
|
-866.57%
|
-3,503.83%
|
-3,500.73%
|
-3,604.91%
|
-2,949.96%
|
-3,383.91%
|
Earnings before Tax (EBT)
1 |
-20.85
|
-20.16
|
-25.91
|
-25.8
|
-30.83
|
-25.28
|
-29.69
|
-22.25
|
-20.21
|
-20.13
|
-20.21
|
-19.77
|
-19.62
|
-17.12
|
-18.01
|
Net income
1 |
-20.85
|
-20.16
|
-25.91
|
-25.8
|
-30.83
|
-25.28
|
-29.69
|
-22.25
|
-20.21
|
-20.13
|
-20.21
|
-19.77
|
-19.62
|
-17.12
|
-18.01
|
Net margin
|
-14,481.94%
|
-7,523.88%
|
-5,443.7%
|
-4,335.97%
|
-4,194.01%
|
-4,899.03%
|
-3,911.33%
|
-2,677.26%
|
-2,043.88%
|
-852.92%
|
-3,329.22%
|
-3,255.49%
|
-3,232.04%
|
-2,913.79%
|
-3,351.35%
|
EPS
2 |
-0.4400
|
-0.4200
|
-0.5400
|
-0.5400
|
-0.6400
|
-0.5000
|
-0.5400
|
-0.4000
|
-0.3700
|
-0.3600
|
-0.3533
|
-0.3083
|
-0.2850
|
-0.2550
|
-0.2575
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/10/22
|
5/4/22
|
8/4/22
|
11/8/22
|
3/1/23
|
5/4/23
|
8/3/23
|
11/9/23
|
3/28/24
|
5/6/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
-
|
205
|
105
|
-
|
127
|
30.9
|
114
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-
|
-59.1
|
-99.9
|
-
|
-92
|
-82
|
-114
|
ROE (net income / shareholders' equity)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
|
-
|
-
|
1.38
|
-
|
-
|
-
|
-
|
Capex / Sales
|
-
|
-
|
66.57%
|
-
|
-
|
-
|
-
|
Announcement Date
|
7/9/21
|
3/10/22
|
3/1/23
|
3/28/24
|
-
|
-
|
-
|
Last Close Price
2.13
USD Average target price
11
USD Spread / Average Target +416.43% Consensus |
1st Jan change
|
Capi.
|
---|
| -29.24% | 117M | | +67.53% | 62.86B | | -0.77% | 41.38B | | +45.66% | 40.38B | | -10.72% | 27.64B | | +13.30% | 26.46B | | -22.79% | 18.9B | | +4.70% | 12.67B | | +24.10% | 12.27B | | +27.41% | 12.07B |
Other Biotechnology & Medical Research
|